Kevin A. D’Amour

Kevin A. D’Amour, Ph.D., is Chief Scientific Officer at Stemson Therapeutics. He has over 20 years experience in cell therapy R&D with specific background in stem cell biology, stem cell differentiation, gene editing, immunology and cell therapy development. Prior to joining Stemson, Kevin was at ViaCyte from 2002 until 2021 and served as the company’s Chief Scientific Officer from 2011 – 2021. At ViaCyte, he lead the development of the first stem cell-derived cell therapies designed to replace pancreatic beta cells for the treatment of type 1 diabetes. Under Kevin’s leadership, ViaCyte took three cell therapy products into the clinic. After his time at ViaCyte, Kevin was Chief Scientific Officer of Brooklyn ImmunoTherapeutics where he focused on developing cell therapies using mRNA-based cell engineering technology. Kevin is a co-author of high-profile publications in renowned scientific journals and an inventor on over 100 patents in the fields of stem cells, cell engineering, and cell therapy. Kevin holds a B.S. in Animal Science from the University of New Hampshire and a Ph.D. in Biology from the University of California, San Diego.